drug

zilucoplan

1 story · latest Oct 15, 2026

Follow zilucoplan. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: FDA approved Oct 2023 · NDA216834
Brand: Zilbrysq

Relationships

Developed by UCB

Timeline

FDA approves efficacy supplement for UCB's Zilbrysq

Oct 15Regulatory decisionUCB zilucoplan

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.